FDA faces new bipartisan push to reverse mifepristone liberalization…

Market overview

Health advocacy groups and anti-abortion lawmakers will intensify efforts to reinstate in-person dispensing requirements for mifepristone. Legal challenges and congressional pressure will likely force the FDA to reconsider its current policy before the end of the year.

regulatory prediction market

Implied probability (Yes)

58%

Source: user-generated

More regulatory markets

• Deep-sea mining approvals will exceed 2025 levels by end-2026 — 72% Yes
• CME Group 24/7 oil futures trading launches by 2026-12-31 — 45% Yes
• Congress passes major campaign finance reform by January 2027 — 60% Yes
• Spain to increase wildfire prevention funding by 20% by 2027 — 70% Yes
• EU AI Act enforcement delays self-improving AI deployment in Europe by 18 months — 60% Yes
• Elon Musk faces congressional censure over Doge health cuts — 68% Yes
• SCOTUS strikes down Chevron deference by Dec 2026 — 72% Yes
• Deep-sea mining moratorium passes UN vote by 2027 — 72% Yes

Browse all regulatory markets →